Trial Profile
An Open-Label, Multiple-Dose Study of the Absorption and Systemic Pharmacokinetics of AN2690 Applied as a 7.5% Solution to All Toenails of Adult Patients With Moderate to Severe Onychomycosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2019
Price :
$35
*
At a glance
- Drugs Tavaborole (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Acronyms ADME I
- Sponsors Anacor Pharmaceuticals
- 19 May 2014 New trial record